
Hydroquinone: Treats selected hyperpigmentation, including melasma, under an appropriate treatment plan. Mandelic Acid: Exfoliates skin; clinical evidence is mainly from professional acne peels.


Choose for diagnosed stubborn pigment with professional guidance and a defined review point.
Consider for exfoliation; evidence for acne comes mainly from supervised peels.
Can you use both?
Mandelic acid can help hydroquinone work but adds irritation. Use on different nights.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Acts on tyrosinase pathways: Hydroquinone suppresses melanin synthesis. Targets excess pigmentation: Appropriate use and monitoring matter.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Loosens outer cells: An acidic formula helps reduce cell adhesion. Promotes shedding: Strength, pH and contact time affect the response.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
4% is a common clinician-directed hydroquinone strength. In the U.S., hydroquinone skin-lightening products are not legally marketed over the counter; higher compounded strengths are not routine starting points.
4%
Clinician-directed strength
Used in melasma treatment and in the approved combination TRI-LUMA. Treatment length and the complete formula require medical guidance.
Choosing a strength: Get a diagnosis and a treatment plan for the pigmented area rather than choosing solely by concentration.
Higher strengths: More is not automatically better. Irritation and blue-black discoloration called ochronosis are important risks, especially with inappropriate or prolonged use.
Formula matters: Single-ingredient creams, compounded blends and TRI-LUMA are different products. A combination containing a steroid or retinoid needs its own instructions.
Mandelic acid skincare and office peels are different products. Controlled acne studies have used professional peels around 40–45%; those strengths are not a target for facial home use.
40–45%
Studied professional peels
Clinician-applied peels studied for mild-to-moderate acne. This describes specific procedures, not a recommended home concentration.
Choosing a strength: For home skincare, use the finished product’s label and your tolerance. Do not assume that a marketed serum reproduces an office peel study.
Higher strengths: Mandelic acid can still burn or irritate skin. Being described as a gentler acid does not make concentrated peels suitable for unsupervised use.
Formula matters: Acidity, vehicle and exposure time influence the effect; percentage alone cannot rank safety or compare mandelic acid with other acids.
Approximate windows, not promises.
First few weeksAssess tolerance first; pigment change is usually slower.
First few weeksAssess tolerance and texture; immediate softness can come from the base formula.
4–8 weeksSome studied regimens begin showing pigment improvement.
4–8 weeksSubtle changes may appear in some tested products; evidence varies.
8–12 weeksA useful review point for benefit and irritation.
8–12 weeksCompare photographs in the same lighting and reassess benefit.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
3–6 monthsPhotoaging trials often need several months; expect modest rather than dramatic change.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
6–12 monthsLong-term evidence is limited for many cosmetic actives; continue only if useful.
Can irritate; prolonged inappropriate use can cause paradoxical darkening (ochronosis).
Can cause stinging, peeling or irritation; avoid active eczema and rosacea flares.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Do not use to lighten normal skin broadly or continue through worsening pigmentation. US nonprescription hydroquinone skin-lightening products are not legally marketed.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
More of it is absorbed through the skin than with most topicals, so it is usually stopped. Azelaic acid is the common substitute. Ask the doctor managing your pregnancy.
Low-strength leave-on acids are generally considered acceptable; avoid peels and ask the clinician managing your pregnancy.
On the skin. The finished product delivers hydroquinone in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Suppresses melanin synthesis through tyrosinase-related activity; targeted use and monitoring matter.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers mandelic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Promotes shedding of surface cells; formula acidity and contact time influence irritation and effect.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Choose for diagnosed stubborn pigment with professional guidance and a defined review point.
The reviewed active-comparator melasma study was small with substantial attrition. Hydroquinone has broader clinical use, but this comparison does not support indefinite treatment or unsupervised high strengths.
Consider for exfoliation; evidence for acne comes mainly from supervised peels.
A 50-person, 12-week trial compared 45% mandelic with 30% salicylic peels. It had no vehicle arm and does not establish the benefit of 5–10% home serums.
Sources